U.S. flag

An official website of the United States government

GTR Home > Tests > Breast Cancer Prognostic Gene Signature Assay (Prosigna®), IVD

Overview

Test order codeHelp: 481210

Test name

Help

Breast Cancer Prognostic Gene Signature Assay (Prosigna®), IVD

Purpose of the test

Help

This is a clinical test intended for Help: Prognostic

Condition

Help

Loading data ......

Click Indication tab for more information.

How to order

Help

Not provided

Specimen source

Paraffin block

Methodology

Help
Molecular Genetics
TTargeted variant analysis
PCR

Summary of what is tested

Loading data ......

Click Methodology tab for more information.

Clinical utility

Help

Not provided

Clinical validity

Help

Not provided

Suggested reading

  • Cardoso et al., 2016
  • Ward et al., 2013
    Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.

Clinical resources

Practice guidelines

  • NICE, 2024
    UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024
  • NCCN, 2023
    Breast Cancer, NCCN Guidelines Version 4.2022
  • NCCN, 2022
    Breast Cancer Screening and Diagnosis, NCCN, Version 1.2022
  • NICE, 2018
    Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34)
  • NICE, 2018
    Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer, NICE, 2018
  • NCCN, 2014
    National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Breast Cancer (See 2022 Update)
  • NICE, 2013
    DG10 Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat: information for the public
  • AHRQ, 2013
    Technology Assessment on Genetic Testing or Molecular Pathology Testing of Cancers with Unknown Primary Site to Determine Origin (ARCHIVED)
  • NCCN, 2011
    NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

Consumer resources

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.